Phase 3 Schizophrenia Clinical Trials
34 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 34 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Negative Symptoms of Schizophrenia
Minerva Neurosciences380 enrolled5 locationsNCT07565428
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences600 enrolled57 locationsNCT07114874
Recruiting
Phase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences560 enrolled20 locationsNCT07227818
Recruiting
Phase 3
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled10 locationsNCT07184619
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Schizophrenia
Bristol-Myers Squibb166 enrolled41 locationsNCT07288567
Recruiting
Phase 3
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Schizophrenia
Central South University400 enrolled8 locationsNCT07045142
Recruiting
Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled15 locationsNCT07105098
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Schizophrenia
Bristol-Myers Squibb250 enrolled56 locationsNCT06882785
Not Yet Recruiting
Phase 3
Schizophrenia Platform for Improving Recovery with Integrated Trials (SPIRIT) - Master Protocol
Schizophrenia
University of Queensland226 enrolled1 locationACTRN12626000583347
Recruiting
Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
SchizophreniaAutism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company400 enrolled59 locationsNCT07424404
Recruiting
Phase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Schizophrenia
LB Pharmaceuticals Inc.456 enrolled13 locationsNCT07363577
Not Yet Recruiting
Phase 3
Schizophrenia and Weight Improvement From Tirzepatide (SWIFT)
ObesitySchizophreniaMetabolic Disorders
University of Queensland106 enrolled1 locationACTRN12626000530325
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Cognitive ImpairmentSchizophrenia; Psychosis
European Group for Research In Schizophrenia171 enrolled16 locationsNCT07084831
Recruiting
Phase 3
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Major Depressive DisorderBipolar DepressionSchizophrenia and Related Disorders
Dr. Inge Winter1,254 enrolled1 locationNCT05603104
Recruiting
Phase 3
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Co., Ltd.100 enrolled1 locationNCT07225712
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968